SU14813 maleateVEGFR/PDGFR/Kit/FLT-3 inhibitor CAS# 849643-15-8 |
- SKLB610
Catalog No.:BCC3647
CAS No.:1125780-41-7
- Sorafenib
Catalog No.:BCN2174
CAS No.:284461-73-0
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- Sorafenib Tosylate
Catalog No.:BCC3654
CAS No.:475207-59-1
- Regorafenib
Catalog No.:BCC3646
CAS No.:755037-03-7
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 849643-15-8 | SDF | Download SDF |
PubChem ID | 11353475 | Appearance | Powder |
Formula | C27H31FN4O8 | M.Wt | 558.56 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (179.03 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | (Z)-but-2-enedioic acid;5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | ||
SMILES | CC1=C(NC(=C1C(=O)NCC(CN2CCOCC2)O)C)C=C3C4=C(C=CC(=C4)F)NC3=O.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | PQPBIMIFGPFTNF-FYOMJGPWSA-N | ||
Standard InChI | InChI=1S/C23H27FN4O4.C4H4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28;5-3(6)1-2-4(7)8/h3-4,9-10,16,26,29H,5-8,11-12H2,1-2H3,(H,25,31)(H,27,30);1-2H,(H,5,6)(H,7,8)/b18-10-;2-1-/t16-;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.In Vitro:SU14813 inhibits ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets. SU14813 inhibits cellular ligand-dependent phosphorylation of VEGFR-2 (transfected NIH 3T3 cells), PDGFR-β (transfected NIH 3T3 cells), KIT (Mo7e cells), and FLT3-internal tandem duplication (FLT3-ITD; MV4;11 cells) as well as FMS/CSF1R (transfected NIH 3T3 cells). SU14813 inhibits VEGFR-2, PDGFR-β, and KIT phosphorylation in porcine aorta endothelial cells overexpressing these targets, with cellular IC50 values of 5.2, 9.9, and 11.2 nM, respectively. SU14813 inhibits the growth of U-118MG with an IC50 of 50 to 100 nM[1].In Vivo:SU14813 inhibits VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion. The plasma concentration required for in vivo target inhibition is estimated to be 100 to 200 ng/mL. Used as monotherapy, SU14813 exhibits broad and potent antitumor activity resulting in regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines. Treatment in combination with docetaxel significantly enhances both the inhibition of primary tumor growth and the survival of the tumor-bearing mice compared with administration of either agent alone[1]. References: |
SU14813 maleate Dilution Calculator
SU14813 maleate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7903 mL | 8.9516 mL | 17.9032 mL | 35.8064 mL | 44.7579 mL |
5 mM | 0.3581 mL | 1.7903 mL | 3.5806 mL | 7.1613 mL | 8.9516 mL |
10 mM | 0.179 mL | 0.8952 mL | 1.7903 mL | 3.5806 mL | 4.4758 mL |
50 mM | 0.0358 mL | 0.179 mL | 0.3581 mL | 0.7161 mL | 0.8952 mL |
100 mM | 0.0179 mL | 0.0895 mL | 0.179 mL | 0.3581 mL | 0.4476 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SU14813 maleate is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3).
- Blepharotriol
Catalog No.:BCN8056
CAS No.:849590-42-7
- Cefquinome
Catalog No.:BCC8910
CAS No.:84957-30-2
- Cevipabulin
Catalog No.:BCC6449
CAS No.:849550-05-6
- Cudraxanthone B
Catalog No.:BCN4398
CAS No.:84955-05-5
- Rosarin
Catalog No.:BCN5967
CAS No.:84954-93-8
- Rosavin
Catalog No.:BCN5968
CAS No.:84954-92-7
- TMPH hydrochloride
Catalog No.:BCC7360
CAS No.:849461-91-2
- 1-(4-Fluorobenzyl)-2-chlorobenzimidazole
Catalog No.:BCC8407
CAS No.:84946-20-3
- Grape Seed Extract
Catalog No.:BCC5317
CAS No.:84929-27-1
- Chinensine B
Catalog No.:BCN4397
CAS No.:849245-34-7
- Cabozantinib (XL184, BMS-907351)
Catalog No.:BCC1264
CAS No.:849217-68-1
- Foretinib (GSK1363089)
Catalog No.:BCC1263
CAS No.:849217-64-7
- Y 134
Catalog No.:BCC7451
CAS No.:849662-80-2
- Rubicordifolin
Catalog No.:BCN7154
CAS No.:849699-55-4
- Deapi-platycoside E
Catalog No.:BCN3320
CAS No.:849758-42-5
- ARP 101
Catalog No.:BCC2371
CAS No.:849773-63-3
- Maohuoside B
Catalog No.:BCN8084
CAS No.:849834-04-4
- 2-Benzoylbenzoic acid
Catalog No.:BCC8561
CAS No.:85-52-9
- Sudan IV;Solvent Red 24
Catalog No.:BCN8379
CAS No.:85-83-6
- Sudan III
Catalog No.:BCN6962
CAS No.:85-86-9
- Altrenogest
Catalog No.:BCC4479
CAS No.:850-52-2
- Methyl 1,6-dihydroxy-3-methylxanthone-8-carboxylate
Catalog No.:BCN7473
CAS No.:85003-85-6
- 5-Methoxysuberenone
Catalog No.:BCN3638
CAS No.:85011-58-1
- Sulfatinib
Catalog No.:BCC8811
CAS No.:1308672-74-3